| Symbol | ALLO |
|---|---|
| Name | ALLOGENE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 650 457-2700 |
| Fax | — |
| — | |
| Website | https://www.allogene.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001737287 |
| Description | Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. Additional info from NASDAQ: |
(99% Neutral) ALLOGENE THERAPEUTICS, INC. (ALLO) Announces Executive Changes
Read moreAllogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
Read moreAllogene Therapeutics Announces Participation in September Investor Conference
Read moreDouglas Earl Martin 🔴 sold 29.7K shares of Allogene Therapeutics, Inc. (ALLO) at $2.12 Transaction Date: Aug 21, 2026 | Filing ID: 058920
Read more📋 Douglas Earl Martin (Officer) plans to sell 30K shares of Allogene Therapeutics, Inc. (at $2.12 each, total $63K) Filed: Aug 21, 2026 | ID: 000023
Read moreNew Form EFFECT - Allogene Therapeutics, Inc. <b>Filed:</b> 2026-08-20 <b>AccNo:</b> 9999999995-26-002725 <b>Size:</b> 1 KB
Read moreNew Form SCHEDULE 13G/A - Allogene Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001231919-26-000912 <b>Size:</b> 30 KB
Read more(30% Negative) ALLOGENE THERAPEUTICS, INC. (ALLO) Reports Q3 2026 Financial Results
Read moreAllogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
Read moreNew Form SCHEDULE 13G/A - Allogene Therapeutics, Inc. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0001296549-26-000008 <b>Size:</b> 38 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07085104 | A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allo… | Phase1 | Systemic Lupus Erythematosus (With and Without Nephritis) | Recruiting | 2025-11-13 | 2032-10-01 | ClinicalTrials.gov |
| NCT06925685 | Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product | — | Hematologic Malignancies | Enrolling_By_Invitation | 2025-01-31 | 2039-01-01 | ClinicalTrials.gov |
| NCT05714345 | Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lym… | Phase2 | Relapsed/Refractory Large B Cell Lymphoma | Terminated | 2023-11-01 | 2024-10-28 | ClinicalTrials.gov |
| NCT05000450 | Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in P… | Phase1 | Relapsed/Refractory Multiple Myeloma | Terminated | 2021-06-06 | 2023-10-11 | ClinicalTrials.gov |
| NCT04696731 | Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear C… | Phase1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | Active_Not_Recruiting | 2021-02-24 | 2030-01-01 | ClinicalTrials.gov |
| NCT04416984 | Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults Wit… | Phase1 | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | Active_Not_Recruiting | 2020-05-21 | 2029-05-01 | ClinicalTrials.gov |
| NCT04093596 | Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Re… | Phase1 | Relapsed/Refractory Multiple Myeloma | Completed | 2019-09-23 | 2025-01-27 | ClinicalTrials.gov |
| NCT03939026 | Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With… | Phase1 | Relapsed/Refractory Large B Cell Lymphoma | Completed | 2019-05-01 | 2025-01-28 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Cyclophosphamide | Other | Phase PHASE1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT04696731 |
| Fludarabine | Other | Phase PHASE1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT04696731 |
| ALLO-647 | Other | Phase PHASE1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT04696731 |
| ALLO-316 | Other | Phase PHASE1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT04696731 |
| Fludarabine | Other | Phase PHASE1 | Systemic Lupus Erythematosus (With and Without Nephritis) | RECRUITING | NCT07085104 |
| Cyclophosphamide | Other | Phase PHASE1 | Systemic Lupus Erythematosus (With and Without Nephritis) | RECRUITING | NCT07085104 |
| ALLO-329 | Other | Phase PHASE1 | Systemic Lupus Erythematosus (With and Without Nephritis) | RECRUITING | NCT07085104 |
| Fludarabine | Other | Phase PHASE1 | Systemic Lupus Erythematosus (With and Without Nephritis) | RECRUITING | NCT07085104 |
| Cyclophosphamide | Other | Phase PHASE1 | Systemic Lupus Erythematosus (With and Without Nephritis) | RECRUITING | NCT07085104 |
| ALLO-329 | Other | Phase PHASE1 | Systemic Lupus Erythematosus (With and Without Nephritis) | RECRUITING | NCT07085104 |
| Cyclophosphamide | Other | Phase PHASE1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT04696731 |
| Fludarabine | Other | Phase PHASE1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT04696731 |
| ALLO-647 | Other | Phase PHASE1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT04696731 |
| ALLO-316 | Other | Phase PHASE1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT04696731 |
| Fludarabine | Other | Phase PHASE1 | Systemic Lupus Erythematosus (With and Without Nephritis) | RECRUITING | NCT07085104 |
| Cyclophosphamide | Other | Phase PHASE1 | Systemic Lupus Erythematosus (With and Without Nephritis) | RECRUITING | NCT07085104 |
| ALLO-329 | Other | Phase PHASE1 | Systemic Lupus Erythematosus (With and Without Nephritis) | RECRUITING | NCT07085104 |
| Nirogacestat | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Fludarabine | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| ALLO-647 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| ALLO-715 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Nirogacestat | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Fludarabine | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| ALLO-647 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| ALLO-715 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Nirogacestat | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Fludarabine | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| ALLO-647 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| ALLO-715 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Nirogacestat | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Fludarabine | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| ALLO-647 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| ALLO-715 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Nirogacestat | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Fludarabine | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| ALLO-647 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| ALLO-715 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Nirogacestat | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Fludarabine | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| ALLO-647 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| ALLO-715 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT04093596 |
| Nirogacestat | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04093596 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04093596 |
| Fludarabine | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04093596 |
| ALLO-647 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04093596 |
| ALLO-715 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04093596 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT05000450 |
| Fludarabine | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT05000450 |
| ALLO-647 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT05000450 |
| ALLO-605 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT05000450 |
| Cyclophosphamide | Other | Phase PHASE1 | Systemic Lupus Erythematosus (With and Without Nephritis) | RECRUITING | NCT07085104 |
| ALLO-329 | Other | Phase PHASE1 | Systemic Lupus Erythematosus (With and Without Nephritis) | RECRUITING | NCT07085104 |
| Cyclophosphamide | Other | Phase PHASE1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT04696731 |
| Fludarabine | Other | Phase PHASE1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT04696731 |
| ALLO-647 | Other | Phase PHASE1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT04696731 |
| ALLO-316 | Other | Phase PHASE1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT04696731 |
| ALLO-501A | Other | Phase PHASE2 | Relapsed/Refractory Large B Cell Lymphoma | TERMINATED | NCT05714345 |
| Cyclophosphamide | Other | Phase PHASE2 | Relapsed/Refractory Large B Cell Lymphoma | TERMINATED | NCT05714345 |
| Fludarabine | Other | Phase PHASE2 | Relapsed/Refractory Large B Cell Lymphoma | TERMINATED | NCT05714345 |
| ALLO-647 | Other | Phase PHASE2 | Relapsed/Refractory Large B Cell Lymphoma | TERMINATED | NCT05714345 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed/Refractory Large B Cell Lymphoma | COMPLETED | NCT03939026 |
| Fludarabine | Other | Phase PHASE1 | Relapsed/Refractory Large B Cell Lymphoma | COMPLETED | NCT03939026 |
| ALLO-647 | Other | Phase PHASE1 | Relapsed/Refractory Large B Cell Lymphoma | COMPLETED | NCT03939026 |
| ALLO-501 | Other | Phase PHASE1 | Relapsed/Refractory Large B Cell Lymphoma | COMPLETED | NCT03939026 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | ACTIVE_NOT_RECRUITING | NCT04416984 |
| Fludarabine | Other | Phase PHASE1 | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | ACTIVE_NOT_RECRUITING | NCT04416984 |
| ALLO-647 | Other | Phase PHASE1 | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | ACTIVE_NOT_RECRUITING | NCT04416984 |
| ALLO-501A | Other | Phase PHASE1 | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | ACTIVE_NOT_RECRUITING | NCT04416984 |
| Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™ | Other | Phase PHASE2 | Large B-cell Lymphoma | RECRUITING | NCT06500273 |
| Cyclophosphamide | Other | Phase PHASE2 | Large B-cell Lymphoma | RECRUITING | NCT06500273 |
| Fludarabine | Other | Phase PHASE2 | Large B-cell Lymphoma | RECRUITING | NCT06500273 |
| cemacabtagene ansegedleucel | Other | Phase PHASE2 | Large B-cell Lymphoma | RECRUITING | NCT06500273 |
| ALLO-329 | GENETIC | Phase PHASE1 | Systemic Lupus Erythematosus (With and Without Nephritis) | RECRUITING | NCT07085104 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Systemic Lupus Erythematosus (With and Without Nephritis) | RECRUITING | NCT07085104 |